Gilead Sciences | GILD - Cost Of Sales

Stock Price
141.11
Daily Change
-0.18 -0.13%
Monthly
-6.80%
Yearly
33.29%
Q1 Forecast
140.61

Gilead Sciences reported $1.62B in Cost of Sales for its fiscal quarter ending in December of 2025.





Cost Of Sales Change Date
AbbVie USD 4.55B 757M Dec/2025
Agios Pharmaceuticals USD 1.88M 199K Dec/2025
ALKERMES USD 46.21M 5.38M Dec/2025
Alnylam Pharmaceuticals USD 267.72M 67.57M Dec/2025
Amgen USD 1.79B 128M Dec/2025
Biogen USD 810.1M 205.1M Sep/2025
BioMarin Pharmaceutical USD 161.56M 16.62M Dec/2025
Bristol-Myers Squibb USD 4.92B 657M Dec/2025
Coherus Biosciences USD 4.04M 324K Dec/2025
Eli Lilly USD 3.37B 363.7M Dec/2025
Gilead Sciences USD 1.62B 50M Dec/2025
GlaxoSmithKline GBP 2.61B 377M Dec/2025
Glaxosmithkline GBP 3.47B 461.37M Dec/2025
Incyte USD 121.18M 22.18M Dec/2025
J&J USD 7.97B 689M Dec/2025
Merck USD 3.32B 531M Dec/2025
Moderna USD 452M 245M Dec/2025
Neurocrine Biosciences USD 17.6M 246.4M Dec/2025
Novartis USD 3.54B 3M Dec/2025
Pfizer USD 6.29B 2.12B Dec/2025
PTC Therapeutics USD 16.3M 7.02M Dec/2025
Puma Biotechnology USD 29.1M 18.44M Sep/2024
Regeneron Pharmaceuticals USD 584.6M 63M Dec/2025
Sangamo BioSciences 2.42M 1.11M Jun/2024
Sanofi EUR 4.29B 421M Dec/2025
Sarepta Therapeutics USD 399.38M 247.93M Dec/2025
United Therapeutics USD 474.7M 373.8M Dec/2025
Vertex Pharmaceuticals USD 466M 51.2M Dec/2025